A Phase 3 interventional study of Tezacaftor/Ivacaftor and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 53 sites in 3 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-09-12.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 23rd largest by enrollment, is one of 3 that started in 2017, is one of 25 in phase 3, and was the 14th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 3 started in 2017.
This study's enrollment of 98 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 47th largest by enrollment of the 116 interventional ones that give a count, is one of 7 that started in 2017, is one of 62 in phase 3, and was the 65th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
Study VX16-661-114 (Study 114) is a Phase 3b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in subjects aged 12 years and older with CF who are homozygous for the F508del mutation on the cystic fibrosis transmembrane conductance regulator gene (CFTR) gene and who discontinued treatment with Orkambi due to respiratory symptoms considered related to treatment. This study is designed to evaluate the safety and efficacy of Tezacaftor/Ivacaftor (TEZ/IVA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo matched to TEZ/IVA fixed-dose combination tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 56 days.
Drug: Placebo
Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed-dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 56 days.
Drug: Tezacaftor/Ivacaftor · Drug: Ivacaftor
Drug pages: Tezacaftor · Ivacaftor
TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
Also known as: TEZ/IVA; VX-661/VX-770
IVA 150 mg tablet.
Also known as: VX-770; IVA
Placebo matched to TEZ/IVA fixed-dose combination tablet.
Placebo matched to IVA tablet.
Incidence of Respiratory Adverse Events of Special Interest (RAESIs)
RAESIs included chest discomfort, dyspnea (shortness of breath), respiration abnormal (chest tightness), asthma, bronchial hyperreactivity, bronchospasm, and wheezing.
Time frame: Day 1 up to Day 84
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Day 28 and Day 56 Measurements
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Baseline, Day 28 and Day 56
Relative Change From Baseline in ppFEV1 at Average of Day 28 and Day 56 Measurements
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Baseline, Day 28 and Day 56
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Day 28 and Day 56 Measurements
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: Baseline, Day 28 and Day 56
Tolerability as Assessed by Number of Participants Who Discontinued Treatment
Time frame: Day 1 through Day 56
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Day 84
| Milestone | Placebo | TEZ/IVA |
|---|---|---|
| Started | 47 | 50 |
| Completed | 46 | 48 |
| Not completed | 1 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Other | 1 | 0 |
RAESIs included chest discomfort, dyspnea (shortness of breath), respiration abnormal (chest tightness), asthma, bronchial hyperreactivity, bronchospasm, and wheezing.
| Participants | Placebo | TEZ/IVA |
|---|---|---|
| Incidence of Respiratory Adverse Events of Special Interest (RAESIs) | 10 | 7 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent predicted of FEV1 | Placebo | TEZ/IVA |
|---|---|---|
| Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Day 28 and Day 56 Measurements | -0.6 ± 3.4 | 2.2 ± 4.8 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent change | Placebo | TEZ/IVA |
|---|---|---|
| Relative Change From Baseline in ppFEV1 at Average of Day 28 and Day 56 Measurements | -1.5 ± 8.1 | 5.2 ± 12.0 |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Placebo | TEZ/IVA |
|---|---|---|
| Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Day 28 and Day 56 Measurements | 4.7 ± 15.4 | 5.7 ± 14.2 |
| Participants | Placebo | TEZ/IVA |
|---|---|---|
| Tolerability as Assessed by Number of Participants Who Discontinued Treatment | 2 | 2 |
| Participants | Placebo | TEZ/IVA |
|---|---|---|
| Participants with AEs | 39 | 37 |
| Participants with SAEs | 9 | 5 |
Collected over Day 1 up to Day 84. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/47 (0%) | 9/47 (19.1%) | 28/47 (59.6%) |
| TEZ/IVA | 1/50 (2%) | 5/50 (10%) | 30/50 (60%) |
| Event | Placebo | TEZ/IVA |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 7/47 | 3/50 |
| Lower respiratory tract infectionInfections and infestations | 1/47 | 0/50 |
| Pericardial effusionCardiac disorders | 1/47 | 0/50 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/47 | 0/50 |
| Pleuritic painRespiratory, thoracic and mediastinal disorders | 1/47 | 0/50 |
| SepsisInfections and infestations | 0/47 | 1/50 |
| ConstipationGastrointestinal disorders | 0/47 | 1/50 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/47 | 1/50 |
| Suicidal ideationPsychiatric disorders | 0/47 | 1/50 |
| Event | Placebo | TEZ/IVA |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 9/47 | 4/50 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/47 | 9/50 |
| HeadacheNervous system disorders | 7/47 | 6/50 |
| NasopharyngitisInfections and infestations | 0/47 | 6/50 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/47 | 5/50 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 5/47 | 2/50 |
| Abdominal pain upperGastrointestinal disorders | 5/47 | 4/50 |
| FatigueGeneral disorders | 4/47 | 2/50 |
| ConstipationGastrointestinal disorders | 0/47 | 4/50 |
| NauseaGastrointestinal disorders | 2/47 | 4/50 |
| Age, Continuous(years) | Placebo | TEZ/IVA | Total |
|---|---|---|---|
| Mean | 33.3 ± 10.0 | 34.3 ± 8.7 | 33.8 ± 9.3 |
| Sex: Female, Male(Participants) | Placebo | TEZ/IVA | Total |
|---|---|---|---|
| Female | 30 | 31 | 61 |
| Male | 17 | 19 | 36 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | TEZ/IVA | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 4 |
| Not Hispanic or Latino | 40 | 41 | 81 |
| Unknown or Not Reported | 4 | 8 | 12 |
| Race (NIH/OMB)(Participants) | Placebo | TEZ/IVA | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 42 | 42 | 84 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 8 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2017 to primary completion in Aug 2018, 14 months.
Results were first posted in Sep 2019, 1 year 1 month after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 14 months is below that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →